Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
about
A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditionsCombotherapy and current concepts as well as future strategies for the treatment of Alzheimer's diseaseDefects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's diseaseNeuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives for the natural combination of both in krill oilDynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseasesBiochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's diseaseMitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.Mitochondria in Alzheimer's Disease and Diabetes-Associated Neurodegeneration: License to Heal!Estrogen deficiency is associated with hippocampal morphological remodeling of early postmenopausal miceGlia Maturation Factor and Mitochondrial Uncoupling Proteins 2 and 4 Expression in the Temporal Cortex of Alzheimer's Disease BrainIn vivo functions of Drp1: lessons learned from yeast genetics and mouse knockoutsQuantitative assessment of mitochondrial DNA copies from whole genome sequencing.GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis.Mitochondrial genome analysis of primary open angle glaucoma patientsAssessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage.Reactive oxygen species mediate visceral pain-related amygdala plasticity and behaviors.Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeuticsDynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficienciesSubcellular Distribution of NAD+ between Cytosol and Mitochondria Determines the Metabolic Profile of Human Cells.Oxidative Stress Is Associated with Neuroinflammation in Animal Models of HIV-1 Tat Neurotoxicity.Mast Cells Release Chemokine CCL2 in Response to Parkinsonian Toxin 1-Methyl-4-Phenyl-Pyridinium (MPP(+))Neuronal inputs and outputs of aging and longevitySelenium in the Therapy of Neurological Diseases. Where is it Going?The dynamic regulation of NAD metabolism in mitochondria.Neuroprotective effect of tea polyphenols on oxyhemoglobin induced subarachnoid hemorrhage in mice.Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS.Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity.Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies.Mitochondrial dynamics changes with age in an APPsw/PS1dE9 mouse model of Alzheimer's disease.The axon initial segment in nervous system disease and injuryMitochondrial dysfunction--a pharmacological target in Alzheimer's disease.Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria.A matter of life, death and diseases: mitochondria from a proteomic perspective.Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy.Mitochondrial filamentation: a therapeutic target for neurodegeneration and aging.Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease.The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms.Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.Dynamin-Related Protein 1 Deficiency Leads to Receptor-Interacting Protein Kinase 3-Mediated Necroptotic Neurodegeneration.
P2860
Q26781560-AC40EA8F-B94B-4D2E-84D7-062EEA342471Q26829899-D4F9E68D-DF67-45C3-87F1-542DE250E958Q27307877-2817B462-32F3-46A9-9BD7-81212516E1EBQ28236740-D5FC23C4-EE8A-48C1-858E-1D9C91802017Q28300234-5F491288-16D3-4E3F-9EC9-DA001D72C394Q28542628-B344573F-C8BE-4DEC-A58D-7F1BAE6C3F75Q30573776-1E4C39DD-3FC4-43E6-8405-E1542A0980BCQ33364882-802135C6-7C8C-40C1-A2B6-2877C7380129Q33591732-001241F8-6422-423B-AA80-5DD5FA6299E8Q33700737-E1FA3A5F-EA81-4E63-BEC5-B4BBC7B87EABQ33723837-5B9B1DE6-8859-4624-B706-E555BA08F58CQ34530591-DAB2C99F-17BD-41A7-BE49-B81CEDB75921Q34741619-96DB91F6-F473-49E3-9218-55F3A5B48FD1Q34935899-DD400872-A37D-4633-9883-869492D34032Q35126945-94F708ED-CCD9-42C5-B769-E24518789088Q35472078-F34DC440-DEE0-4AA2-9A9F-D99C93782C6AQ35737647-0F95AF6E-B946-45A9-9ABE-23774E652A53Q35918643-3C37A47C-64C8-47AB-BA3C-6B339CCB17F3Q36282881-4C89EDB1-17CD-4D37-A4CE-69BDF5338472Q36335033-E1F5FB6F-12D4-497F-926E-59AFE01CD24BQ36805502-88DBCC5A-5256-49D6-8E92-77D0B26F5876Q36817447-BFA25165-B4D0-4F1B-97C5-4D64E1CB12CDQ36872331-95F301C8-28C4-4DF5-927E-0C3D834F428BQ36933021-BE27FEF8-7190-43FB-B047-E339DF00E2E7Q36938876-A3584150-33F7-4D34-896A-EC0EE3852E0BQ37413126-B73515AD-8672-485C-8C7F-204ABAC1183CQ37439356-4A3467E0-B65B-4F2A-9EFA-246BC25B94D2Q37586163-9FA9152C-C78A-4B01-8DB4-6BB9877AF3A1Q37659147-AA66AAEE-17B7-4236-8AD3-FDAEE507B612Q37958904-34E31767-9FC3-4DA1-AB9E-8CF2FC07DA91Q38007107-29CE31FC-8A0C-47FE-973E-99232FE85A9AQ38019418-684BF12D-459B-4AB0-85B2-70537B1416D1Q38081957-3E1DF4FA-07E1-4CD2-A6E7-872284EFFC7CQ38086474-33363E94-E9BB-4D6E-874E-8FC1D73E29DDQ38127332-92D5CD2B-EC9F-41B2-97D1-8B449772048AQ38414169-2BED8BFA-4A77-4E77-93A7-611F0D95D8A9Q38716156-346A9653-C8BC-48E1-B9C1-E924D88018D3Q38878661-ECD0FA8E-2747-4BD1-819C-05C09DF25038Q38994300-410B1D2B-0589-457B-BA99-C771E0218F36Q39377642-6099EE24-F1D1-41AE-91B9-F8CA58D2CD52
P2860
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
@ast
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
@en
type
label
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
@ast
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
@en
prefLabel
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
@ast
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
@en
P2860
P1476
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
@en
P2093
P2860
P304
P356
10.2174/156720511795745401
P577
2011-06-01T00:00:00Z